New antibiotic may protect against neurodegenerative diseases: Study

An antibiotic, minocycline, can increase the lifespan of roundworms by preventing the build-up of proteins during ageing, a study has found.

Protein aggregation causes several progressive age-related brain diseases, including amyotrophic lateral sclerosis, Alzheimer's, Parkinson's and prion disease.

The study, published in the journal eLife, shows that minocycline prevents this build-up even in older animals with age-impaired stress-response pathways.

The number of proteins in a cell is balanced by the rate of protein manufacture and disposal, called proteostasis. As we age, proteostasis becomes impaired.

"It would be great if there were a way to enhance proteostasis and extend lifespan and health, by treating older people at the first sign of neurodegenerative symptoms or disease markers such as protein build-up," said Gregory Solis, a graduate student at Scripps Research, US.

"In this study, we investigated whether minocycline can reduce protein aggregation and extend lifespan in animals that already have impaired proteostasis," said Solis.

The researchers first tested 21 different molecules known to extend lifespan in young and old Caenorhabditis elegans (C elegans) worms.

They found that all of these molecules prolonged the lives of young worms; however, the only drug that worked on the older worms was minocycline.

To find out why, they looked at whether minocycline had any effect on protein aggregation in the worms.

They treated young and old worms with either water or minocycline and then measured two proteins called alpha-synuclein and amyloid-beta, which are known to build up in Parkinson's and Alzheimer's disease, respectively.

Regardless of the worms' age, those treated with minocycline had reduced aggregation of both proteins as they grew older without even without the activation of stress responses.

The team next turned its attention to the mechanism behind this discovery.

First, they looked at whether minocycline switches on stress-signalling proteins that are impaired in older worms, but they found the drug actually reduces their activity.

Next, they studied whether it turns off the cell's protein-disposal processes, but this was not its mode of action either.

When they used a chemical probe to see how minocycline affects the major protein-regulating molecules in the cell, it revealed that minocycline directly affects the protein-manufacturing machinery of the cell, known as the ribosome.

This was true in worms, as well as mouse and human cells.

Finally, the team used worms with increased or decreased protein-manufacturing activity and studied how this altered the effect of minocycline on protein levels and lifespan.

As predicted, in mutant worms where protein manufacturing was already decreased, they found that a lower dose of minocycline was needed to further reduce protein levels and extend lifespan.

In worms where protein manufacturing was increased, the opposite was seen.

This suggested that minocycline extends lifespan by controlling the rate of protein manufacturing at the ribosome.

"We have identified minocycline as a drug that can extend lifespan and improve protein balance in already-ageing worms," said Michael Petrascheck, Associate Professor at Scripps Research.

"Our study reveals how minocycline prevents protein aggregation and lays the foundations for drug-development efforts aimed at optimising this already-approved drug for a range of neurodegenerative diseases," Petrascheck said.